During the last session, Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)’s traded shares were 0.87 million, with the beta value of the company hitting 0.39. At the end of the trading day, the stock’s price was $273.91, reflecting an intraday gain of 2.75% or $7.32. The 52-week high for the ALNY share is $304.39, that puts it down -11.13 from that peak though still a striking 48.17% gain since the share price plummeted to a 52-week low of $141.98. The company’s market capitalization is $35.16B, and the average intraday trading volume over the past 10 days was 0.89 million shares, and the average trade volume was 858.63K shares over the past three months.
Alnylam Pharmaceuticals Inc (ALNY) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.79. ALNY has a Sell rating from 0 analyst(s) out of 20 analysts who have looked at this stock. 4 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 16 recommend a Buy rating for it.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) trade information
Alnylam Pharmaceuticals Inc (ALNY) registered a 2.75% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.75% in intraday trading to $273.91, hitting a weekly high. The stock’s 5-day price performance is -3.84%, and it has moved by 1.63% in 30 days. Based on these gigs, the overall price performance for the year is 74.46%. The short interest in Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) is 4.84 million shares and it means that shorts have 7.6 day(s) to cover.
The consensus price target of analysts on Wall Street is $253, which implies a decrease of -8.26% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $96 and $400 respectively. As a result, ALNY is trading at a discount of -46.03% off the target high and 64.95% off the low.
Alnylam Pharmaceuticals Inc (ALNY) estimates and forecasts
Statistics show that Alnylam Pharmaceuticals Inc has outperformed its competitors in share price, compared to the industry in which it operates. Alnylam Pharmaceuticals Inc (ALNY) shares have gone up 79.81% during the last six months, with a year-to-date growth rate more than the industry average at 80.97% against 17.10.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 14.18%. While earnings are projected to return 43.83% in 2024.
ALNY Dividends
Alnylam Pharmaceuticals Inc is due to release its next quarterly earnings on 2025-Feb-13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)’s Major holders
Alnylam Pharmaceuticals Inc insiders own 0.42% of total outstanding shares while institutional holders control 96.10%, with the float percentage being 96.50%. CAPITAL WORLD INVESTORS is the largest shareholder of the company, while 849.0 institutions own stock in it. As of 2024-06-30, the company held over 14.97 million shares (or 11.869% of all shares), a total value of $3.64 billion in shares.
The next largest institutional holding, with 12.51 million shares, is of VANGUARD GROUP INC’s that is approximately 9.9159% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $3.04 billion.
